Journal Article

Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience

Alyansky, Alexander Leonidovich, Afanasyev, Boris Vladimirovich, Paina, Olesya Vladimirovna, Polushin, Alexey Yurievich, Bykova, Tatyana Alexandrovna, Kucher, Maxim Anatolievich, Pevtcov, Dmitrii Eduardovich, Mikhailova, Natalia Borisovna, Popova, Marina Olegovna, Ivanova, Natalia Evgenievna, Bondarenko, Sergei Nicolaevich, Bogomolny, Maxim Pavlovich, Moiseev, Ivan Sergeevich, Osipova, Anna Alekseevna, Goloshchapov, Oleg Valerievich, Vlasova, Yulia Yurievna, Babenko, Elena Vitalievna, Volkova, Alisa Georgievna, Kazantsev, Ilya Viktorovich, Vladovskaya, Maria Dmidrievna, Semenova, Elena Vladimirovna, Vitrishchak, Alina Alexandrovna, Mamaev, Nikolai Nikolaevich, Chukhlovin, Alexei Borisovich, Kulagin, Alexander Dmitrievich, Morozova, Elena Vladislavovna, Zubarovskaya, Ludmila Stepanovna, Gindina, Tatiana Leonidovna, Slesarchuk, Olga Alexandrovna, Estrina, Maria Arkadievna, Smirnova, Anna Gennadyevna, Stelmakh, Liliya Vladimirovna

2023

Overview

In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).

• Publisher: MDPI AG,MDPI
• Subject: Acute lymphoblastic leukemia / Acute myeloid leukemia / Analysis / Anemia / Aplastic anemia / Chronic lymphocytic leukemia / Confidence intervals / Developing countries / Development and progression / Disease / Donors / Ewings sarcoma / Health aspects / Hematopoietic stem cells / LDCs / Leukemia / Lymphatic leukemia / Lymphoma / Lymphomas / Morphology / Mortality / Multiple myeloma / Multivariate analysis / Non-Hodgkin's lymphoma / Nuclear power plants / Patients / Research centers / Solid tumors / Stem cell transplantation / Stem cells / Survival analysis / Transplantation / Trends / Tumors